Security
AVTX · Avalo Therapeutics, Inc.
AVTXNASDAQCommon stockCurrentCIK 1534120Updated Sep 25, 2026
Name history
Cerecor Inc. · through Aug 18, 2021
AVTX price & chart
Loading TradingView…
NASDAQ:AVTX on TradingView ↗In the news
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 116,458,000Source | 150,732,000Source | 20,993,000Source | 33,367,000Source |
| GoodwillUSD | 10,502,000Source | 10,502,000Source | 10,502,000Source | 14,409,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | 0Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 15,858,000Source | 134,546,000Source | 7,415,000Source | 13,172,000Source |
| Accounts ReceivableUSD | — | — | — | 0Source |
| Inventory, NetUSD | — | — | 0Source | 20,000Source |
| Assets, CurrentUSD | 105,286,000Source | 138,890,000Source | 8,395,000Source | 16,416,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,913,000Source | 3,714,000Source | 843,000Source | 1,290,000Source |
| Operating Lease, Right-of-Use AssetUSD | 336,000Source | 741,000Source | 1,329,000Source | 1,750,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 33,409,000Source | 17,700,000Source | 13,689,000Source | 44,282,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 18,000Source | 10,000Source | 1,000Source | 9,000Source |
| Additional Paid in CapitalUSD | 531,485,000Source | 503,285,000Source | 342,437,000Source | 292,900,000Source |
| Retained Earnings (Accumulated Deficit)USD | -448,522,000Source | -370,263,000Source | -335,134,000Source | -303,824,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 68,000Source | — | — | — |
| Stockholders' Equity Attributable to ParentUSD | 83,049,000Source | 133,032,000Source | 7,304,000Source | -10,915,000Source |
| Liabilities and EquityUSD | 116,458,000Source | 150,732,000Source | 20,993,000Source | 33,367,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 12,940,000Source | 6,960,000Source | 4,618,000Source | 22,114,000Source |
| Operating Lease, Liability, CurrentUSD | 392,000Source | 568,000Source | 537,000Source | 532,000Source |
| Accounts Payable, CurrentUSD | 137,000Source | 283,000Source | 446,000Source | 2,882,000Source |
| Operating Lease, Liability, NoncurrentUSD | 35,000Source | 350,000Source | 1,366,000Source | 1,711,000Source |
| Deferred Income Tax Liabilities, NetUSD | 434,000Source | 270,000Source | 155,000Source | 141,000Source |
| Other Liabilities, NoncurrentUSD | 35,000Source | 350,000Source | 1,366,000Source | 1,711,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 98,300,000Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | 434,000Source | 270,000Source | 155,000Source | 141,000Source |
| Short-term InvestmentsUSD | 82,478,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 344,000Source | 169,000Source | 158,000Source | 166,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 13,621,000Source | 5,852,000Source | 3,477,000Source | 7,554,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | 0Source | -1,060,000Source |
| Increase (Decrease) in InventoriesUSD | — | 0Source | -20,000Source | -18,000Source |
| Increase (Decrease) in Accounts PayableUSD | -146,000Source | -163,000Source | -2,436,000Source | -487,000Source |
| Deferred Income Tax Expense (Benefit)USD | 165,000Source | 114,000Source | 14,000Source | 28,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -51,458,000Source | -49,056,000Source | -30,680,000Source | -26,751,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -81,720,000Source | 356,000Source | -133,000Source | -95,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | 95,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 510,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 14,587,000Source | 175,849,000Source | 25,042,000Source | -14,699,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -118,591,000Source | 127,149,000Source | -5,771,000Source | -41,545,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 16,105,000Source | 134,696,000Source | 7,547,000Source | 13,318,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 0Source | 1,925,000Source | 2,931,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 13,621,000Source | 5,852,000Source | 3,475,000Source | 7,554,000Source |
| Amortization of Intangible AssetsUSD | — | — | 0Source | 38,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 98,300,000Source | — | — | — |
| DepreciationUSD | 300,000Source | 200,000Source | 200,000Source | 100,000Source |
| Gain (Loss) on Termination of LeaseUSD | 0Source | 309,000Source | — | — |
| General and Administrative ExpenseUSD | 22,900,000Source | 17,241,000Source | — | 20,711,000Source |
| GoodwillUSD | 10,502,000Source | 10,502,000Source | 10,502,000Source | 14,409,000Source |
| Goodwill, Impairment LossUSD | — | 0Source | 3,907,000Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -41,658,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | 165,000Source | 114,000Source | 14,000Source | 28,000Source |
| Liability for Unpaid Claims and Claims Adjustment Expense, Incurred ClaimsUSD | — | — | — | 500,000Source |
| Net Income (Loss) Attributable to ParentUSD | -78,259,000Source | -35,129,000Source | -31,544,000Source | -41,658,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -35,129,000Source | — | — |
| Nonoperating Income (Expense)USD | -5,169,000Source | 33,497,000Source | -4,179,000Source | -4,190,000Source |
| Other Nonoperating Income (Expense)USD | — | -5,000Source | -42,000Source | -20,000Source |
| Payments for Repurchase of WarrantsUSD | 0Source | 1,734,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | 14,762,000Source | 0Source | 46,200,000Source | 0Source |
| Proceeds from Stock Options ExercisedUSD | 774,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 59,000Source | 441,000Source | 1,924,000Source | 18,051,000Source |
| Cost of RevenueUSD | — | — | 1,284,000Source | 3,434,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 10,300,000Source | — |
| Operating Income (Loss)USD | -72,925,000Source | -68,512,000Source | -27,351,000Source | -37,440,000Source |
| Other Nonoperating Income (Expense)USD | — | -5,000Source | -42,000Source | -20,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -78,094,000Source | -35,015,000Source | -31,530,000Source | — |
| Income Tax Expense (Benefit)USD | 165,000Source | 114,000Source | 14,000Source | 28,000Source |
| Net Income (Loss) Attributable to ParentUSD | -78,259,000Source | -35,129,000Source | -31,544,000Source | -41,658,000Source |
| Earnings Per Share, BasicUSD per share | -5.84Source | -7.94Source | -114Source | -4.43Source |
| Earnings Per Share, DilutedUSD per share | -5.84Source | -20.91Source | -114Source | -4.43Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 13,404,830Source | 4,426,149Source | 277,727Source | 9,408,477Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 13,404,830Source | 7,496,389Source | 277,727Source | 9,408,477Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | 0Source | 38,000Source |
| Costs and ExpensesUSD | 72,984,000Source | 68,953,000Source | 29,275,000Source | 55,491,000Source |
| Current Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | 22,900,000Source | 17,241,000Source | — | 20,711,000Source |
| Goodwill, Impairment LossUSD | — | 0Source | 3,907,000Source | — |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | — | -41,630,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -41,658,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | 0Source |
| Interest Income (Expense), Nonoperating, NetUSD | 4,351,000Source | 3,317,000Source | -3,417,000Source | -4,170,000Source |
| Liability for Unpaid Claims and Claims Adjustment Expense, Incurred ClaimsUSD | — | — | — | 500,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -35,129,000Source | — | — |
| Nonoperating Income (Expense)USD | -5,169,000Source | 33,497,000Source | -4,179,000Source | -4,190,000Source |
Filing attachments
tm2613717d1_ex4-1.htm · 8-K · 2026-05-07
EX-4.1 3 tm2613717d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 AVALO THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: [__], 2026 Avalo Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___], or its permitted registered assigns (the “Holder”), is entitled, sub…
Read attachment ↗ex-991_dec2025xavalocorp.htm · 8-K · 2025-12-02
EX-99.1 2 ex-991_dec2025xavalocorp.htm EX-99.1 ex-991_dec2025xavalocorp ne mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs. CORPORATE OVERVIEW December 2025 | AVALO THERAPEUTICS, INC. (AVTX) Exhibit 99.1 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such …
Read attachment ↗ex-991_avalocorporatepre.htm · 8-K · 2025-05-08
EX-99.1 2 ex-991_avalocorporatepre.htm EX-99.1 ex-991_avalocorporatepre May 2025 Corporate Presentation Avalo Therapeutics, Inc. (AVTX) Exhibit 99.1 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward- looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based …
Read attachment ↗ex-991_avalocorporatepre.htm · 8-K · 2025-01-13
EX-99.1 2 ex-991_avalocorporatepre.htm EX-99.1 ex-991_avalocorporatepre January 2025 Corporate Presentation Avalo Therapeutics, Inc. (AVTX) Exhibit 99.1 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward- looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change ba…
Read attachment ↗